['heterozygous familial hypercholesterolemia']
['placebo', 'alirocumab']

        Inclusion Criteria:

          1. Men and women ≥18 years of age at the time of the screening visit

          2. Diagnosis of HeFH (Heterozygous familial hypercholesterolemia)

          3. Currently undergoing LDL (low-density lipoprotein) apheresis therapy QW (weekly) or
             Q2W (every 2 weeks) or at least 8 weeks prior to the screening visit

        Exclusion Criteria:

          1. Homozygous FH (familial hypercholesterolemia)

          2. Background medical LMT (lipid-modifying therapy) (if applicable) that has not been
             stable for at least 8 weeks prior to the screening visit

          3. LDL apheresis schedule/ apheresis settings that have not been stable for at least 8
             weeks prior to the screening visit

          4. An LDL apheresis schedule other than QW to Q2W

          5. Initiation of a new exercise program or exercise that has not remained stable within 8
             weeks prior to the screening visit (week -2)

          6. Initiation of a new diet or a diet that has not been stable within 8 weeks prior to
             the screening visit (week -2)

          7. Use of nutraceuticals or over-the-counter therapies known to affect lipids, at a
             dose/amount that has not been stable for at least 8 weeks prior to the screening visit
             (week -2), or between the screening and randomization visit

          8. Presence of any clinically significant uncontrolled endocrine disease known to
             influence serum lipids or lipoproteins

          9. Known history of a positive test for human immunodeficiency virus

         10. Use of any active investigational drugs within 1 month or 5 half-lives of screening,
             whichever is longer

         11. Patients who have been treated with at least 1 dose of alirocumab or any other
             anti-PCSK9 monoclonal antibody in any other clinical studies

         12. Pregnant or breastfeeding women
      